[New generation chemotherapy in the treatment of operated gastric cancer--an alternative to traditional chemotherapy].
Gastric cancer remains one of the most difficult tumour type despite his relative reduction of his global incidence, it remains on of the most deadly cancer. The latest advances in therapy of the gastric cancer ameliorate the results in terms of survival. In our prospective, non-randomized study, we enrolled 40 patients with gastric adenocarcinoma stage IB to IV (M0) who were surgically treated, treated with chemoradioterapy, but with chemotherapy modified by ECX (epirubicine, cisplatine, xeloda) which is now considered standard in metastatic setting. We report the toxicities and possible predictive factors to toxicity. The ECX regimen seems to be a reliable alternative to the traditional regimen with convenient toxicity and therapeutic index.